

European Medicines Agency Evaluation of Medicines for Human Use

This document was valid from October 2007 until May 2013. It is now superseded by a new version adopted by the HMPC on 14 May 2013 and published on the EMA website.

London, 31 October 2007 Doc. Ref. EMEA/HMPC/5341/2007

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

FINAL

COMMUNITY HERBAL MONOGRAPH ON MELISSA OFFICINALIS L., FOLIUM

DISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	March 2007 May 2007
ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION	8 May 2007
END OF CONSULTATION (DEADLINE FOR COMMENTS)	15 August 2007
REDISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	October 2007
ADOPTION BY HMPC	31 October 2007

KEYWORDS	Herbal medicinal products; HMPC; Community herbal monographs; traditional use; <i>Melissa officinalis</i> L.; Melissae folium; melissa leaf

COMMUNITY HERBAL MONOGRAPH ON MELISSA OFFICINALIS L., FOLIUM

1. NAME OF THE MEDICINAL PRODUCT

To be specified for the individual finished product.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION $^{1,\,2}$

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Melissa officinalis L., folium (melissa leaf)
	i) Herbal substance Cut, dried
	ii) Herbal preparations - powdered herbal substance
	- Tincture (1:5; extraction solvent ethanol 45% V/V or m/m)
	- Liquid extract (1:1; extraction solvent ethanol 45% V/V/ or m/m)
	iii) Dry extracts that correspond to extracts
	mentioned under ii)

3. PHARMACEUTICAL FORM

Well-established use	<u>Traditional use</u>
	Herbal substance or herbal preparations in solid or liquid dosage forms for oral use or as herbal tea.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

©EMEA 2008 2/5

¹ The material complies with the Ph. Eur. monograph (ref. 01/2005: 1447)

² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Well-established use	Traditional use
	a) Traditional herbal medicinal product for relief of mild symptoms of mental stress and to aid sleep.
	b) Traditional herbal medicinal product for symptomatic treatment of mild gastrointestinal complaints including bloating and flatulence.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	<u>Traditional use</u>
	Posology
	Adolescents over 12 years of age, adults, elderly
	Cut or powdered herbal substance: 1.5 - 4.5 g of herbal substance 1 - 3 times per day.
	Herbal tea: To make an infusion, pour 150 ml of boiling water over 1.5 - 4.5 g of herbal substance.
	Steep for 5 - 15 minutes. To be taken 1 - 3 times
	daily.
	Tincture: 2 - 6 ml 1 - 3 times daily. Liquid extract: 2 - 4 ml 1 - 3 times daily.
	•
	Dried water or ethanol (45%) extracts in doses corresponding to the posologies for tea, tincture and liquid extracts above.
	The use in children under 12 years of age is not recommended (see 4.4. Special warnings and precautions for use).
	Duration of use
	If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

©EMEA 2008 3/5

4.3. Contraindications

Well-established use	<u>Traditional use</u>
	Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Well-established use	<u>Traditional use</u>
	The use in children under 12 years of age is not recommended because data are not sufficient and medical advice should be sought.
	For tinctures and liquid extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the
	label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	<u>Traditional use</u>
	No data available.

4.6. Pregnancy and lactation

Well-established use	<u>Traditional use</u>
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	<u>Traditional use</u>
	May impair ability to drive and use machines. Affected patients should not drive or operate machinery.

4.8. Undesirable effects

Well-established use	<u>Traditional use</u>
	None known.
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

©EMEA 2008 4/5

4.9. Overdose

Well-established use	<u>Traditional use</u>
	No case of overdose has been reported.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of
	Directive 2001/83/EC as amended, unless
	necessary for the safe use of the product.
	Data from in vitro and animal studies indicate that
	the water extract of <i>Melissa officinalis</i> may
	inhibit the activity of thyroid stimulating hormone
	(TSH). The clinical relevance of these findings is
	not known.
	Tests on reproductive toxicity, genotoxicity and
	carcinogenicity have not been performed.

6. PHARMACEUTICAL PARTICULARS

Well-established use	<u>Traditional use</u>
	Not applicable.

7. DATE OF COMPILATION/LAST REVISION

31 October 2007

©EMEA 2008 5/5